Cyclacel Pharmaceutical Inc (CYCC)

[Value_Investor]

Can CYCC test its most recent high $6.00 in the next week?

[Value_Investor]

CYCC should run in the next week unless any bad news kicks in...

[Value_Investor]

Hyper Oversold --- from $20.xx to $3.23?

[Value_Investor]

CYCC has bounced to $3.87 so far from the New Bottom $3.23!

[02opida]

will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m

[dinogreeves]

3-4 catalyst awaiting this year for this thing, I would not doubt we will be trading in the teens soon before the end of the year, especially the news regarding their COVID phase in Scotland.

[stock1ace1]

Riding the waves !

[dinogreeves]

News very soon.

[dinogreeves]

News pending thus the move.

[stock1ace1]

Breakout watch

[dinogreeves]

Should get news soon.

[02opida]

Cyclacel ’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

2020-07-13 07:00 ET - News Release

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against

CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC –

-- Data builds on growing body of evidence indicating the promise of dual CDK2/9 inhibition --

BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, July 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced publication of a peer-reviewed study of fadraciclib, in PLOS ONE. The publication, authored by scientists from Cyclacel and The Institute of Cancer Research, London, describes the discovery of fadraciclib and shows its ability to target CDK2 and CDK9, leading to broad therapeutic potential.

“The published findings strengthen the mechanistic rationale for fadraciclib’s potential as an anti-cancer therapy. Building upon previous research in CDK pathways, including the roles of cyclin E, MCL1 and MYC overexpression, the paper highlights the benefits of inhibiting both CDK2 and CDK9, two complementary cancer pathways,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “Independent findings reported at the ASCO20 Virtual Scientific Program corroborate the attractiveness of this dual targeting approach. Based on recently disclosed clinical data fadraciclib is establishing a leadership position among apoptosis enabling compounds in clinical development. We are encouraged by observations of single agent anticancer activity in our clinical studies. Initial clinical data with oral fadraciclib show concordance with intravenous pharmacokinetics. In parallel with evaluating fadraciclib in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), we are executing a precision medicine strategy to evaluate fadraciclib in patients with solid tumors, with study enrollment expected to begin by Q1 2021.”

“These exciting new findings revealing fadraciclib’s chemical structure and describing its relevant anti-cancer properties, reflect the highly productive collaboration of ICR with Cyclacel to discover and develop innovative cancer treatments,” said Professor Paul Workman, FMedSci, FRS, study co-author and Chief Executive and President, The Institute of Cancer Research, London, UK. “As a potent and selective inhibitor of CDK2 and CDK9, we believe our cumulative findings to-date support fadraciclib’s ability to address key cancer pathways in solid tumors and leukaemias, indicating its potential as a new targeted anti-cancer therapy.”

Cyclin-dependent kinases (CDKs) exist in many isoforms and as key cell cycle regulators can play a critical role in cancer growth. This preclinical characterization of fadraciclib includes its potency and selectivity against CDK2 and CDK9 in vitro and in a broad range of cancer cell lines including AML, breast and colorectal. Further in vivo efficacy was demonstrated in leukemia xenograft models.

Experimental results support fadraciclib’s anti-cancer activity through CDK2/9 inhibition. In breast cancer cell lines, short-pulse treatment with fadraciclib showed preferential activity against transformed cells over normal cells. This finding supports the compound’s potential benefit in cancers addicted to cyclin E which can be rationally targeted by CDK2 inhibition. In AML models, fadraciclib was effective in inhibiting CDK9 and suppressing the MCL1 protein to induce apoptosis or programmed cell death of leukemia cells. Fadraciclib also demonstrated synergy with BCL2 inhibitors such as venetoclax in AML cells. In subcutaneous mouse xenograft models of AML and MLLr-AML, nearly 100% tumor growth inhibition was achieved with oral administration of fadraciclib at pharmacological doses.

[stock1ace1]

Keep on selling me cheapies

[stock1ace1]

Ill take em $4.35 thanks

[stock1ace1]

We got a clown selling @4.50 p/m lol

[stock1ace1]

Tomorrow it should go chart it :D

[stock1ace1]

The stage is set waiting on volume or news :D patiently waiting !

[stock1ace1]

Got 4.60s filled today ready for a breakout any day know :D

[stock1ace1]

8k out on voting matters

[stock1ace1]

Its about to go SM ;) locked and loaded

[interloper]

Clearly running now, short term target And Resistance is near 5.80

[Frankestin]

wow 22 pt

[Frankestin]

https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/cyclacel-pharmaceuticals-and-university-of-edinburgh/

[Liam859]

$4.20

[symphon1]

OK tks

[benchman]

Earnings beat expectations.

[symphon1]

Have you an idea for this rise in premarket ?
Tks

[Crazy Money]

CYCC

[KingT]

Whew it was all about timing here and Spiros past performance is what got me out with mehga profits.

Im on to the next one .. follow me my man

[CollegeGrad22]

Try $4’s

[bcapps66]

They can't even get to the $5 mark of their offering...

[bcapps66]

LOL!

[Multi_Pennies]

https://newsfilter.io/a/2a51151029f0ba4d9a06a5937d3237b1

[Penny_God]

8.00 gap fill coming

[CollegeGrad22]

I just hate it for whoever bought those $19’s yesterday. Let’s just hope they cut their losses early. Seen too many of these sharp drops off of peaks lately. Not worth holding any runners. Take your gains early if possible and move on to the next

[symphon1]

In order for someone to be interested in the proposed financing, the share price must be higher than $ 5 because otherwise buying an action directly on the market costs less.
So the company will be forced to publish very quickly news to raise the price (The offering is expected to close on April 23, 2020)

[bcapps66]

This has to give back a buck or two of today's losses, right? Pretty please!

[bcapps66]

I've smacked it twice (6K then 2K more) in hopes of this coming back a little bit given the offer was for $5 a share. But alas, it didn't help and I'm not going to attempt to catch a falling knife.

[TheFinalCD]

that doesnt mean diddly in this corrupt market


they short anyways

[TheFinalCD]

CYCC 4.24 you must be happy that you sold 10.60 now

Message in reply to:

got stopped out at 10.60. Lesson learned. Take smaller profits smile Should have sold out at 12.80's while I could have

[TheFinalCD]

smart move.... you didnt jump in prior to the offering

Message in reply to:

I may scoop some $7-8’s here. Kinda worried about an offering tho. Not worth holding overnight

[Penny_God]

Smack that ask

[CollegeGrad22]

Thank goodness I adhered to my senses of an offering coming on this yesterday and didn’t buy

[symphon1]

https://ih.advfn.com/stock-market/NASDAQ/cyclacel-pharmaceuticals-CYCC/stock-news/82272623/cyclacel-announces-pricing-of-20-million-public-o

that's the real reason for this huge drop
scandalous masquerade

[symphon1]

ok tks for your patience

[Frankestin]

Now CYCC have 20/22 mil $
3 drugs
they don't spend much on development... for the moment
other 20 mil pending with warrant at 5$ strike
Soon news on cyc065
NOW MC 22 mil

[symphon1]

do you think it will go up in a few days?

[Frankestin]

For now i m a bag holder!
Just sell if i have to recovery loss for no pay tax

[Bustajoy]

It’ll make it go down. The company is trying to raise money, so they release a lot of shares into the market to raise capital at a price lower than the price from yesterday. Companies do this all the time. It’ll be up to the investor to decide if they want to get in now, or cut their losses and move on

[symphon1]

this should make the stock go up and not go down , no ?